Carlos Ontiveros

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor–Induced Synthetic Lethality”.

Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor–Induced Synthetic Lethality

Cancer Research(2022)10.1158/0008-5472.can-21-2076

N/A

0DataRank · unranked

70 citations

Jacob T. Boyd, Clare Murray, Julia Saifetiarova, Bárbara de la Peña Avalos, Cody M. Rogers +15 more

Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents

International Journal of Molecular Sciences(2022)10.3390/ijms23095129

N/A

0DataRank · unranked

11 citations

Eva Galvan, Carlos Ontiveros, Yilun Deng, Haiyan Bai, Álvaro Padrón +6 more

Alternative splicing of the SUMO transcripts contributes to the regulation of the cellular SUMOylation system and produces messages coding for protein isoforms functionally distinct from the prototypical SUMO proteins

Research Square(2022)10.21203/rs.3.rs-2011524/v1

N/A

0DataRank · unranked

0 citations

Andrea García-Morin, Rebeca Orozco-Sepúlveda, Carlos Ontiveros, Alejandra Flores, Arely V. Diaz +7 more

501 Anti-PDL2 uses IL17-driven interferon-gamma to treat aged but not young cutaneous melanoma-bearing mice, and treats other tumors in an age- and TME-dependent manner

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0501

N/A

0DataRank · unranked

0 citations

Yilun Deng, Clare Murray, Carlos Ontiveros, Álvaro Padrón, Sladjana Skopelja‐Gardner +4 more

453 Pharmacologic tumor PDL1 depletion as a translational approach to inhibit tumor-intrinsic PDL1 signals and create novel treatment vulnerabilities

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0453

N/A

0DataRank · unranked

0 citations

Haiyan Bai, Anand Kornepati, Carlos Ontiveros, Yilun Deng, Álvaro Padrón +4 more

1428 Melanocyte-intrinsic PDL1 promotes tumorigenesis and progression in a novel autochthonous melanoma model

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.1428

N/A

0DataRank · unranked

0 citations

Yilun Deng, Anand Kornepati, Clare Murray, Mary Jo Turk, Harshita B. Gupta +3 more

Alternative splicing of the SUMO1/2/3 transcripts affects cellular SUMOylation and produces functionally distinct SUMO protein isoforms

Scientific Reports(2023)10.1038/s41598-023-29357-7

N/A

0DataRank · unranked

20 citations

Andrea García-Morin, Rebeca Orozco-Sepúlveda, Carlos Ontiveros, Alejandra Flores, Arely V. Diaz +7 more

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-004871

N/A

0DataRank · unranked

12 citations

Álvaro Padrón, Yilun Deng, Yiji Liao, Clare J Murray, Carlos Ontiveros +9 more

1488 Melanoma cell-of-origin PDL1 promotes early tumor progression and distinct immune outcomes in a novel autochthonous NRAS-mutant melanoma model

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.1488

N/A

0DataRank · unranked

0 citations

Clare Murray, Haiyan Bai, Mary Jo Turk, Tyler J. Curiel, Carlos Ontiveros

Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors

Molecular Cancer(2024)10.1186/s12943-024-02147-z

N/A

0DataRank · unranked

11 citations

Anand Kornepati, Carlos Ontiveros, Yiji Liao, Bárbara de la Peña Avalos, Cody M. Rogers +25 more